Refractory Lupus Nephritis

Immunology·MeSH: Lupus Nephritis

3 drugs in development·2 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
chemotherapy agents	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2/Phase 3(2)

Drug	Company
kyv-101	Kyverna Therapeutics, Inc. (KYTX)
tak-007	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

BioSniper tracks 3 drugs in development for Refractory Lupus Nephritis across 2 companies.

There are 2 clinical trials targeting Refractory Lupus Nephritis tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.